MorphoSys' Monjuvi Shows Long-Term Durable Response In Blood Cancer Settings
MorphoSys' Monjuvi Shows Long-Term Durable Response In Blood Cancer Settings
Morphosys的Monjuvi在血癌治疗中显示出长期持久的反应
- MorphoSys AG (NASDAQ:MOR) announced data from the ongoing L-MIND study showing that Monjuvi (tafasitamab-cxix) regime provided long-term efficacy in relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated for at least two years, including six patients on treatment for five years or more.
- The regime includes Monjuvi plus lenalidomide followed by Monjuvi monotherapy.
- Additionally, the frequency of adverse events declined after patients transitioned from combination therapy to monotherapy.
- A complete response was observed in 23 of the 27 patients who had undergone treatment, including four who were refractory to their primary therapy. A partial response was seen in four patients, two of whom were still on treatment at the data cutoff.
- Most adverse events were mild or moderate during combination and monotherapy treatment. During monotherapy, patients experienced a lower frequency of all-grade and grade 3 or higher adverse events.
- The most common adverse events with combination therapy were neutropenia and diarrhea, which declined after patients switched to monotherapy. They remained the most common adverse events in the first two years of monotherapy.
- Tafasitamab is co-marketed by Incyte Corporation (NASDAQ:INCY).
- Price Action: MOR shares are up 2.19% at $5.61 during the premarket session on the last check Thursday.
- MorphoSys AG (NASDAQ:MOR) announced data from the ongoing L-MIND study showing that Monjuvi (tafasitamab-cxix) regime provided long-term efficacy in relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated for at least two years, including six patients on treatment for five years or more.
- The regime includes Monjuvi plus lenalidomide followed by Monjuvi monotherapy.
- Additionally, the frequency of adverse events declined after patients transitioned from combination therapy to monotherapy.
- A complete response was observed in 23 of the 27 patients who had undergone treatment, including four who were refractory to their primary therapy. A partial response was seen in four patients, two of whom were still on treatment at the data cutoff.
- Most adverse events were mild or moderate during combination and monotherapy treatment. During monotherapy, patients experienced a lower frequency of all-grade and grade 3 or higher adverse events.
- The most common adverse events with combination therapy were neutropenia and diarrhea, which declined after patients switched to monotherapy. They remained the most common adverse events in the first two years of monotherapy.
- Tafasitamab is co-marketed by Incyte Corporation (NASDAQ:INCY).
- Price Action: MOR shares are up 2.19% at $5.61 during the premarket session on the last check Thursday.
- Morphosys公司纳斯达克股票代码：MOR)公布的正在进行的L-Mind研究数据显示，孟居维(他法他单抗-cxix)方案对治疗至少两年的复发或难治性(R/R)弥漫性大B细胞淋巴瘤(DLBCL)具有长期疗效，其中包括6名治疗5年或更长时间的患者。
- 该方案包括孟加拉度胺加来那度胺，然后是孟朱维单一疗法。
- 此外，在患者从联合治疗过渡到单一治疗后，不良事件的频率下降。
- 在接受治疗的27名患者中，有23人观察到完全缓解，其中4人对最初的治疗无效。四名患者出现部分缓解，其中两人在数据截止时仍在接受治疗。
- 在联合治疗和单一治疗期间，大多数不良事件都是轻微或中度的。在单一治疗期间，患者经历所有级别和3级或更高级别不良事件的频率较低。
- 联合治疗最常见的不良反应是中性粒细胞减少和腹泻，在患者转向单一治疗后，这些不良反应有所下降。在单一疗法的头两年，它们仍然是最常见的不良事件。
- Tafasitamab由以下公司联合营销Incell公司(纳斯达克：Incy)。
- 价格行动：在周四最后一次检查的盘前交易中，MOR股价上涨2.19%，至5.61美元。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
风险及免责提示
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
知道了
风险及免责提示
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
知道了
抢沙发
0 0 0
赞大爱笑哭社会社会Emm心碎怒
轻触选择心情
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧
点击这里分享给好友
暂无评论，快来抢沙发吧！